Aclaris Therapeutics (NASDAQ:ACRS) – Leerink Swann lowered their FY2018 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Monday, March 12th, Zacks Investment Research reports. Leerink Swann analyst S. Fernandez now expects that the biotechnology company will post earnings per share of ($4.35) for the year, down from their prior forecast of ($3.89). Leerink Swann currently has a “Outperform” rating and a $52.00 target price on the stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ FY2019 earnings at ($3.75) EPS, FY2020 earnings at ($3.10) EPS, FY2021 earnings at $1.06 EPS and FY2022 earnings at $4.82 EPS.
A number of other analysts have also weighed in on the stock. BidaskClub lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald restated a “buy” rating and set a $50.00 price target on shares of Aclaris Therapeutics in a research report on Monday, March 12th. Finally, Guggenheim initiated coverage on shares of Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 price target on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $43.50.
Shares of NASDAQ:ACRS traded down $0.20 during midday trading on Thursday, reaching $16.46. The company’s stock had a trading volume of 194,484 shares, compared to its average volume of 311,977. The firm has a market capitalization of $514.82, a P/E ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a twelve month low of $16.01 and a twelve month high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.80 million.
Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new stake in Aclaris Therapeutics during the third quarter valued at $142,000. Teacher Retirement System of Texas acquired a new stake in Aclaris Therapeutics during the fourth quarter valued at $200,000. Voya Investment Management LLC acquired a new stake in Aclaris Therapeutics during the second quarter valued at $247,000. Trexquant Investment LP acquired a new stake in Aclaris Therapeutics during the third quarter valued at $247,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Aclaris Therapeutics during the fourth quarter valued at $244,000. Institutional investors own 92.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Aclaris Therapeutics (NASDAQ:ACRS) Expected to Earn FY2018 Earnings of ($4.35) Per Share” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/equities-analysts-offer-predictions-for-aclaris-therapeutics-incs-fy2018-earnings-acrs.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.